CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that clinical and pre-clinical data on its first-in-class histone methyltransferase (HMT) inhibitors will be highlighted in oral and poster presentations at the 56th annual meeting of the American Society of Hematology (ASH), to be held December 6-9 in San Francisco, Calif.
“Epizyme continues its scientific and clinical leadership in the field of HMTs, and the next two months will be particularly important for us as we share clinical data from our two lead programs, with a late-breaking oral presentation of our EPZ-6438 data at the EORTC-NCI-AACR Symposium in November and the oral presentation of the EPZ-5676 data at ASH in December,” said Robert Gould, Ph.D., President and Chief Executive Officer, Epizyme. “We are also pleased to be able to share at ASH pre-clinical data on our first-in-class PRMT5 inhibitor, a promising development candidate from the Epizyme pipeline, as well as pharmacokinetic modeling for the EPZ-5676 pediatric Phase 1 study.”
Help employers find you! Check out all the jobs and post your resume.
